Sanara MedTech EBITDA Margin 2014-2024 | SMTI
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Sanara MedTech (SMTI) over the last 10 years. The current EBITDA margin for Sanara MedTech as of December 31, 2024 is .
| Sanara MedTech EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-12-31 | $0.09B | $0.00B | -2.30% |
| 2024-09-30 | $0.08B | $0.00B | -2.53% |
| 2024-06-30 | $0.07B | $0.00B | -1.37% |
| 2024-03-31 | $0.07B | 0 | 0.00% |
| 2023-12-31 | $0.07B | 0 | 0.00% |
| 2023-09-30 | $0.06B | $0.00B | -4.76% |
| 2023-06-30 | $0.06B | $-0.01B | -8.33% |
| 2023-03-31 | $0.05B | $-0.01B | -12.96% |
| 2022-12-31 | $0.05B | $-0.01B | -21.74% |
| 2022-09-30 | $0.04B | $-0.01B | -28.95% |
| 2022-06-30 | $0.03B | $-0.01B | -35.48% |
| 2022-03-31 | $0.03B | $-0.01B | -33.33% |
| 2021-12-31 | $0.02B | $-0.01B | -29.17% |
| 2021-09-30 | $0.02B | $-0.01B | -22.73% |
| 2021-06-30 | $0.02B | $0.00B | -20.00% |
| 2021-03-31 | $0.02B | $0.00B | -23.53% |
| 2020-12-31 | $0.02B | $-0.01B | -31.25% |
| 2020-09-30 | $0.01B | $-0.01B | -35.71% |
| 2020-06-30 | $0.01B | $-0.01B | -38.46% |
| 2020-03-31 | $0.01B | $0.00B | -30.77% |
| 2019-12-31 | $0.01B | $0.00B | -18.18% |
| 2019-09-30 | $0.01B | $0.00B | -10.00% |
| 2019-06-30 | $0.01B | 0 | 0.00% |
| 2019-03-31 | $0.01B | 0 | 0.00% |
| 2018-12-31 | $0.01B | 0 | 0.00% |
| 2018-09-30 | $0.01B | 0 | 0.00% |
| 2018-06-30 | $0.01B | 0 | 0.00% |
| 2018-03-31 | $0.01B | 0 | 0.00% |
| 2017-12-31 | $0.01B | 0 | 0.00% |
| 2017-03-31 | $0.00B | $0.00B | 33.33% |
| 2016-06-30 | $0.00B | $0.00B | 100.00% |
| 2016-03-31 | $0.00B | $0.00B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.292B | $0.087B |
| Wound Management Technologies Inc. develops and markets wound care products. It develops, markets and distributes biotechnology products to physicians, hospitals and clinics. The Company markets collagen-based products for the treatment of pressure ulcers, diabetic ulcers, surgical wounds, ulcers due to arterial insufficiency, traumatic wounds, first and second degree burns and superficial wounds. It sells and distributes CellerateRX(R) Surgical Activated Collagen(R) Adjuvant as well as HemaQuell(R) Resorbable Bone Hemostat. Wound Management Technologies Inc. is based in Fort Worth, Texas. | |||